| 1507 |
National Cancer Institute |
Html |
en |
Extragonadal Germ Cell Tumors Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of extragonadal germ cell tumors. |
| residual mass | 0.384023 |
| large tumor volume | 0.30085 |
| residual disease. | 0.273583 |
| recurrent testicular cancer. | 0.3175 |
| cisplatin-based chemotherapy regimens | 0.371374 |
| PDQ cancer information | 0.391809 |
| bulky tumors | 0.328858 |
| nonseminoma germ cell | 0.421124 |
| cell tumors. | 0.272309 |
| nonseminomatous germ cell | 0.40313 |
| clinical trials | 0.311324 |
| relatively small tumors | 0.373793 |
| germ cells | 0.335003 |
| particularly young individuals | 0.307507 |
| Initial chemotherapy | 0.290755 |
| cancer information summary | 0.37005 |
| breast cancer prevention | 0.298248 |
| careful testicular examination | 0.334354 |
| Initial debulking surgery | 0.299396 |
| extragonadal primary tumors | 0.367991 |
| patients | 0.377174 |
| BEP regimen | 0.273424 |
| NCI’s PDQ | 0.288373 |
| PDQ Adult Treatment | 0.321273 |
|
| NCI PDQ cancer | 0.337916 |
| Craniospinal radiation therapy | 0.306681 |
| extragonadal germ cell | 0.679693 |
| international germ cell | 0.403901 |
| tumor prognostic classification | 0.317369 |
| overall survival rates | 0.302813 |
| long-term disease-free survival | 0.296962 |
| chemotherapy course | 0.295979 |
| major clinical trial | 0.309884 |
| autologous bone marrow | 0.294582 |
| advanced disseminated germ | 0.372421 |
| seminomatous germ cell | 0.403127 |
| nonseminomatous extragonadal germ | 0.370944 |
| testicular seminoma | 0.333059 |
| serum alpha fetoprotein | 0.309001 |
| high-risk patients | 0.281542 |
| larger residual masses | 0.321492 |
| National Cancer Institute | 0.298826 |
| PDQ documents | 0.279503 |
| nonseminoma testicular cancer | 0.332786 |
| nonlocalized tumors | 0.326576 |
| germ cell tumors | 0.92252 |
| residual mass posttreatment | 0.32699 |
| Hematologic toxic effects | 0.298226 |
|
CLICK HERE |
| 1581 |
National Cancer Institute |
Html |
en |
Thyroid Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of thyroid cancer. |
| thyroid hormone | 0.462109 |
| thyroid cells | 0.459144 |
| thyroid hormone levels | 0.441028 |
| body | 0.475956 |
| thyroid nodules | 0.440882 |
| thyroid hormone replacement | 0.418097 |
| type | 0.402327 |
| PDQ cancer information | 0.417269 |
| clinical trial search | 0.44196 |
| clinical trials | 0.712208 |
| thyroid cancer spreads | 0.460066 |
| radioactive iodine therapy | 0.447344 |
| cancer information summary | 0.398763 |
| clinical trial | 0.54371 |
| thyroid disease | 0.440863 |
| patients | 0.405549 |
| fine-needle aspiration biopsy | 0.401121 |
| sentinel lymph node | 0.409752 |
| thyroid tumor | 0.430395 |
| lymph nodes | 0.45279 |
| thyroid cancer cells | 0.479847 |
| thyroid cancer treatment | 0.491155 |
| radiation therapy | 0.478836 |
| medullary thyroid cancer | 0.563411 |
| tyrosine kinase inhibitor | 0.42467 |
|
| thyroid scan | 0.39797 |
| treatment | 0.554504 |
| childhood thyroid cancer | 0.480138 |
| thyroid nodule | 0.461177 |
| follicular thyroid cells | 0.442093 |
| metastatic thyroid cancer | 0.461409 |
| healthy thyroid | 0.426685 |
| undifferentiated thyroid cancer | 0.481926 |
| thyroid cancer | 0.866042 |
| cancer cells | 0.55043 |
| thyroid tissue | 0.43819 |
| familial medullary thyroid | 0.436692 |
| anaplastic thyroid cancer | 0.503212 |
| National Cancer Institute | 0.411413 |
| Thyroid hormones | 0.426342 |
| external radiation therapy | 0.459156 |
| papillary thyroid cancers | 0.4232 |
| differentiated thyroid cancer | 0.481235 |
| thyroid uses iodine | 0.446079 |
| cancer clinical trials | 0.453504 |
| stage | 0.433394 |
| tumor | 0.440267 |
| cancer | 0.979846 |
| information | 0.45122 |
|
CLICK HERE |
| 1704 |
National Cancer Institute |
Html |
en |
Psychological Stress and Cancer |
A fact sheet that describes the effects of stress on the body, the results of research on the relationship between stress and cancer, and information about coping with stress. |
| Sood AK | 0.622496 |
| cancer treatment | 0.603243 |
| primary breast cancer | 0.597411 |
| Antoni MH | 0.570507 |
| human cancer cells | 0.605494 |
| family member | 0.588007 |
| psychological distress | 0.593032 |
| fact sheet | 0.615559 |
| mammary fat pads | 0.570769 |
| emotional pressure | 0.583244 |
| Health care providers | 0.574848 |
| risky behaviors | 0.581446 |
| cancer metastasis | 0.572171 |
| social support | 0.574381 |
| triple-negative breast cancer | 0.658004 |
| various psychological factors | 0.615469 |
| Lutgendorf SK | 0.681275 |
| cancer patients | 0.656706 |
| cancer survival | 0.572148 |
| stress cause cancer | 0.708673 |
| blood sugar levels | 0.578812 |
| Clinical Oncology | 0.599718 |
| speed heart rate | 0.575901 |
| ovarian carcinoma patients | 0.577415 |
|
| higher rates | 0.57609 |
| specific psychological conditions | 0.622117 |
| Psychological Bulletin | 0.579687 |
| elevated tumor norepinephrine | 0.576809 |
| psychological stress | 0.974362 |
| beta blockers | 0.5732 |
| normal life activities | 0.583211 |
| physical health problems | 0.585785 |
| drinking alcohol | 0.576593 |
| cancer outcomes | 0.570999 |
| biobehavioral signaling pathways | 0.570101 |
| stress management techniques | 0.670628 |
| clinical health psychologist | 0.575253 |
| Cancer Research | 0.5705 |
| stress hormone norepinephrine | 0.675379 |
| poorer clinical outcomes | 0.584728 |
| stress hormones | 0.675405 |
| people | 0.602029 |
| certain stress hormones | 0.663467 |
| New patient-centered care | 0.571423 |
| close family member | 0.58133 |
| Related Resources | 0.579385 |
| et al | 0.674807 |
| Related Resources section | 0.573303 |
|
CLICK HERE |
| 1804 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de seno (mama). |
| Surgical Adjuvant Breast | 0.311283 |
| node-positive breast | 0.305691 |
| susceptibility to breast | 0.306299 |
| results from | 0.304936 |
| node-negative breast carcinoma | 0.307067 |
| linfáticos internos mamarios | 0.304657 |
| invasive breast | 0.310223 |
| MammaPrint breast | 0.305772 |
| metástasis manifiesta | 0.303936 |
| Breast Cancer Family | 0.311467 |
| invasive breast carcinoma | 0.30652 |
| breast magnetic resonance | 0.305716 |
| Breast Cancer Linkage | 0.318171 |
| with node-negative breast | 0.307174 |
| brca2 mutation | 0.31001 |
| early breast | 0.305558 |
| Metástasis ipsilateral rodaderab | 0.30419 |
| Cancer Linkage Consortium | 0.309543 |
| risk factors | 0.310931 |
| ganglio centinela | 0.304343 |
| mucinous breast carcinomas | 0.305818 |
| Natl Cancer Inst | 0.352497 |
| breast carcinomas | 0.328163 |
| Women's Health Initiative | 0.304548 |
| node-negative breast | 0.315228 |
|
| N2b Metástasis | 0.303847 |
| from benign breast | 0.306434 |
| N2a Metástasis | 0.30385 |
| BRCA2 mutation carriers | 0.309625 |
| investigation into cancer | 0.309168 |
| Bilateral breast carcinoma | 0.306729 |
| ganglios positivos.Se | 0.305633 |
| Lancet Oncol | 0.305043 |
| contralateral breast | 0.320411 |
| lobular breast | 0.305977 |
| benign breast | 0.312903 |
| ganglio linfático centinela | 0.333143 |
| ganglios satélites | 0.30541 |
| Cancer Staging Manual | 0.308858 |
| Cancer Res Treat | 0.315484 |
| Clin Oncol | 0.389208 |
| breast carcinomas distinguish | 0.305804 |
| breast cancer | 0.999811 |
| Relat Cancer | 0.305724 |
| BRCA2-associated breast | 0.305731 |
| with invasive breast | 0.307222 |
| family history | 0.30714 |
| AJCC Cancer Staging | 0.309184 |
| Breast Cancer Res | 0.348498 |
|
CLICK HERE |
| 1832 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de vagina (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de vagina. |
| Obstet Gynecol | 0.283662 |
| Lippincott Williams | 0.242575 |
| vagina funcional | 0.243946 |
| berek js | 0.239666 |
| Carlone M | 0.228988 |
| prognostic factors | 0.719083 |
| vaginal cancer | 0.473271 |
| Sin embargo | 0.237061 |
| American Cancer Society | 0.229383 |
| Frank SJ | 0.247276 |
| Definitive radiotherapy | 0.277726 |
| institutional experience | 0.233025 |
| Radiat Oncol Biol | 0.893767 |
| DeVita VT Jr | 0.277942 |
| Camel HM | 0.230789 |
| Jhingran A | 0.245715 |
| Gynecol Oncol | 0.996446 |
| Rosenberg SA | 0.240229 |
| primary invasive squamous | 0.2365 |
| squamous carcinoma | 0.334954 |
| Lee P | 0.243278 |
| Galakatos AE | 0.229807 |
| vagina treated with | 0.406995 |
| primary carcinoma | 0.405837 |
| Markman MA | 0.223742 |
|
| estadio ii | 0.224737 |
| Seski J | 0.269409 |
| vaginal intraepithelial neoplasia | 0.27229 |
| Perez CA | 0.260508 |
| Wheeler JA | 0.267137 |
| Cancer Staging Manual | 0.259578 |
| Levenback C | 0.24589 |
| Definitive irradiation | 0.237883 |
| Chen AS | 0.271634 |
| Eifel PJ | 0.224915 |
| PDQ Tratamiento | 0.250686 |
| New York | 0.251038 |
| long-term evaluation | 0.231124 |
| 9th ed | 0.223747 |
| Zagars GK | 0.268986 |
| Oncol Biol Phys | 0.938039 |
| invasive squamous carcinoma | 0.314957 |
| Dundas G | 0.228633 |
| Treat Options Oncol | 0.229038 |
| cuello uterino | 0.451234 |
| Gynecol Cancer | 0.242612 |
| Twenty-year review | 0.228463 |
| AJCC Cancer Staging | 0.261483 |
| squamous cell carcinoma | 0.643647 |
|
CLICK HERE |
| 1833 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores carcinoides gastrointestinales (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los tumores carcinoides gastrointestinales. |
| metastatic carcinoid tumor | 0.417651 |
| carcinoides gi | 0.793345 |
| enfermedad cardÃaca carcinoide | 0.432281 |
| carcinoides duodenales | 0.478754 |
| células ec | 0.425941 |
| tracto gi | 0.460962 |
| Sin embargo | 0.46213 |
| tumores carcinoides gi | 0.491452 |
| PDQ Tumores neuroendocrinos | 0.416768 |
| imaging features with | 0.416291 |
| células neuroendocrinas gi | 0.414118 |
| marcadores carcinoides | 0.432817 |
| Exp Clin Cancer | 0.413418 |
| Cancer Res | 0.421273 |
| Res Clin Endocrinol | 0.414031 |
| Clin Gastroenterol | 0.414029 |
| sÃntomas carcinoides | 0.431545 |
| Pract Res Clin | 0.438075 |
| sÃndrome carcinoideo | 0.506176 |
| Clin Cancer Res | 0.414666 |
| patients with | 0.502884 |
| carcinoid tumors | 0.605663 |
| Best Pract Res | 0.431995 |
| Clin Endocrinol Metab | 0.422923 |
| carcinoid heart | 0.423722 |
|
| carcinoides celulares cse | 0.43559 |
| carcinoide celular cse | 0.415154 |
| tumores carcinoides | 0.966863 |
| neuroendocrine tumors | 0.59007 |
| TNE pancreáticos | 0.414445 |
| gastrointestinal tract | 0.419836 |
| tumores carcinoides gastrointestinales | 0.615452 |
| Surg Pathol | 0.422847 |
| Dig Dis Sci | 0.415197 |
| tumores tipo | 0.415164 |
| multiple endocrine neoplasia | 0.418143 |
| CSE tipo | 0.414261 |
| TNE GI | 0.460772 |
| tumores neuroendocrinos | 0.4479 |
| carcinoides esporádicos gi | 0.445952 |
| Surg Oncol | 0.418143 |
| with von recklinghausen | 0.424868 |
| somatostatin receptor | 0.413855 |
| neuroendocrine tumour | 0.454787 |
| tumores neuroendocrinos pancreáticos | 0.419002 |
| carcinoid tumor with | 0.413498 |
| Acad Sci | 0.415384 |
| gastrointestinal carcinoids | 0.415688 |
| tumores duodenales | 0.41576 |
|
CLICK HERE |
| 1934 |
National Cancer Institute |
Html |
es |
Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo. |
| siguientes procedimientos | 0.506474 |
| células madre | 0.526262 |
| pequeña cantidad | 0.50899 |
| siguientes especialistas | 0.504251 |
| siguientes tipos | 0.504112 |
| rayos x | 0.523233 |
| tejido óseo | 0.519779 |
| enlace drugs approved | 0.505077 |
| suficiente tejido | 0.503088 |
| fibroso maligno óseo | 0.821835 |
| efectos tardÃos | 0.529504 |
| PDQ Efectos tardÃos | 0.509684 |
| National Cancer Institute | 0.502454 |
| siguientes riesgos | 0.501964 |
| médula ósea también | 0.505126 |
|
| Instituto Nacional | 0.509248 |
| PDQ Tratamiento | 0.523403 |
| determinados cambios | 0.501954 |
| alta potencia | 0.503883 |
| nuevos tipos | 0.503233 |
| Physician Data Query | 0.509387 |
| cáncer óseo | 0.512408 |
| siguientes situaciones | 0.505889 |
| Bone Cancer | 0.502772 |
| siguientes enlaces | 0.502451 |
| células sanguÃneas maduras | 0.509706 |
| célula madre | 0.502683 |
| siguientes pruebas | 0.512226 |
| fibroso maligno | 0.960799 |
|
CLICK HERE |
| 1945 |
National Cancer Institute |
Html |
es |
Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de los problemas de salud que aparecen una vez que termina el tratamiento del cáncer. |
| cancer statistics | 0.312893 |
| among adult survivors | 0.309342 |
| health insurance | 0.30576 |
| childhood leukemia survivors | 0.314627 |
| Marrow Transplant Survivor | 0.306695 |
| largo plazo | 0.353459 |
| Cancer Survivor cohort | 0.310798 |
| CA Cancer | 0.308516 |
| group long-term follow-up | 0.307764 |
| mortality among 5-year | 0.309974 |
| health conditions | 0.3067 |
| young adult cancers | 0.387348 |
| late mortality | 0.309117 |
| Ness KK | 0.312945 |
| among childhood cancer | 0.329959 |
| adult survivors | 0.341543 |
| Hudson MM | 0.322937 |
| among survivors | 0.313213 |
| British Childhood Cancer | 0.315849 |
| utilization among long-term | 0.306183 |
| childhood cancer | 0.973475 |
| cancer survivor study | 0.608871 |
| late effects | 0.312383 |
| SEER Cancer Statistics | 0.308306 |
| long-term survivors | 0.338777 |
|
| health care utilization | 0.307102 |
| Survivor Study cohort | 0.310239 |
| chronic health conditions | 0.305835 |
| among adolescent survivors | 0.308292 |
| Care Cancer | 0.309376 |
| among 5-year survivors | 0.328567 |
| Pediatr Blood Cancer | 0.42011 |
| oncology group long-term | 0.310223 |
| adolescent cancers | 0.313982 |
| efectos tardÃos | 0.375703 |
| survivors research program | 0.306998 |
| report from | 0.396085 |
| National Cancer Institute | 0.308232 |
| Oeffinger KC | 0.306859 |
| health care | 0.314251 |
| mortality among survivors | 0.308816 |
| Clin Oncol | 0.375569 |
| childhood cancer survivor | 0.872407 |
| medical care | 0.307228 |
| among long-term survivors | 0.315379 |
| late mortality among | 0.306982 |
| long-term follow-up guidelines | 0.320022 |
| Outcomes Among Childhood | 0.309917 |
| children's oncology group | 0.433388 |
|
CLICK HERE |
| 15908 |
National Cancer Institute |
Html |
es |
Laetrilo (amigdalina) (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso del laetrilo (amigdalina) como tratamiento para personas con cáncer. |
| Natl Acad Sci | 0.351583 |
| institute's retrospective laetrile | 0.328712 |
| treated with laetrile | 0.349302 |
| Exp Med Surg | 0.328157 |
| Promoting poison | 0.33939 |
| antitumor activity | 0.465434 |
| cases treated with | 0.28668 |
| treatment with laetrile | 0.295229 |
| with laetrile | 0.90547 |
| CA Cancer | 0.770829 |
| Acta Unio Int | 0.423146 |
| Cancer Industry | 0.474642 |
| Med Hypotheses | 0.298922 |
| Cancer Commission | 0.379224 |
| Estados Unidos | 0.752083 |
| Amygdalin induces apoptosis | 0.284053 |
| Navarro MD | 0.430756 |
| Unio Int Contr | 0.427919 |
| Five years | 0.324596 |
| Ellison NM | 0.316229 |
| Bickis IJ | 0.282987 |
| Acad Med | 0.304051 |
| Ames MM | 0.502122 |
| Laetrile toxicity studies | 0.333014 |
| Med Assoc | 0.356472 |
|
| Diss Abstr Int | 0.346583 |
| years experience with | 0.456942 |
| Proc Natl Acad | 0.355643 |
| vÃa oral | 0.317497 |
| Laetrile toxicity | 0.342269 |
| retrospective laetrile analysis | 0.331541 |
| Cancer Establishment | 0.478533 |
| experience with laetrile | 0.549066 |
| Dorr RT | 0.337868 |
| Cancer Institute retrospective | 0.411789 |
| Unproven methods | 0.542254 |
| Treat Rep | 0.798281 |
| current status | 0.343299 |
| Intern Med | 0.566133 |
| Kovach JS | 0.535271 |
| with laetrile therapy | 0.559394 |
| Clin Nutr | 0.378962 |
| Int Contr Cancrum | 0.427916 |
| laetrile intoxication | 0.281414 |
| Moertel CG | 0.440121 |
| Herbert V | 0.324024 |
| NCI Laetrile Review | 0.334924 |
| Paxinos J | 0.340814 |
| Med Chem | 0.296011 |
|
CLICK HERE |
| 16839 |
National Cancer Institute |
Html |
en |
Previous NCI Alliance Grantees |
The NCI Alliance for Nanotechnology in Cancer has funded a multitude of research and training grants since 2005. Find here a list of all of these high impact projects. |
| cancer-related nanotechnology research | 0.909204 |
| initiative | 0.300481 |
| private organizations | 0.515908 |
| Focus | 0.261214 |
| National Cancer Institute | 0.829641 |
|
| clinical practice | 0.510503 |
| clinicians | 0.293138 |
| areas | 0.260532 |
| NCI Alliance | 0.657758 |
| major commitment | 0.597371 |
|
CLICK HERE |